Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 1, 2011, Pages 43-49

  Tajika, Tetsuya ^a   Isowaki, Akiharu ^b   Sakaki, Hideyuki ^a  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

^b Senju USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFLUPREDNATE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CHOROID; CILIARY BODY; CONJUNCTIVA; CORNEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; EMULSION; EXPERIMENTAL RABBIT; IRIS; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RADIOACTIVITY; RETINA; SCLERA; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; URINARY EXCRETION;

ABSORPTION; ANIMALS; AUTORADIOGRAPHY; EMULSIONS; EYE; FECES; FLUPREDNISOLONE; INSTILLATION, DRUG; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; RABBITS; TISSUE DISTRIBUTION; TRITIUM;

EID: 79951965818     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0093     Document Type: Article

References (32)

1. Bordor, N., Harget, A.J., and Phillips E.W. Structure-activity relationships in the anti-inflamatory steroid: a pattern-recognition approach. J. Med. Chem. 26:318-328, 1983.
2. Takahashi, K., Arai, Y., and Kadowaki, S. Anti-inflammatory activity of difluprednate, a topical anti-inflammatory steroid (1), effect of local and subcutaneous administration. Oyo Yakuri (Pharmacometrics) 29:343-353, 1985.
3. Takahashi, K., Kadowaki, S., Arai, Y., and Sugasawa, K. Anti-inflammatory activity of difluprednate, a topical anti-inflammatory steroid (2), effect of topical application of difluprednate ointment (DFBA). Oyo Yakuri (Pharmacometrics) 29:355-362, 1985.
4. Navarro, J., Girard, J., Lacour, C., Unkovic, J., and Lafille, C. Pharmacological study of a new anti-inflammatory steroid, difluprednate (CM 9155). Arzneim Forsch 28:2302-2311, 1978. (Pubitemid 9093238)
5. Fujino, A., et al. Studies on the metabolic fate of difluprednate (DFBA) (1): absorption, distribution and excretion after subcutaneous administration to rats and rabbits. Oyo Yakuri (Pharmacometrics) 29:687-699, 1985.
6. Fujino, A., Ohta, S., Shinozawa, N., et al. Studies on the metabolic fate of difluprenate (DFBA) (2): absorption, distribution and excretion after dermal application to rats and rabbits. Oyo Yakuri (Pharmacometrics) 29:701-712, 1985.
7. Fujino, A., Ohta, S., Shibata, K., et al. Studies on the metabolic fate of difluprednate (DFBA) (3): metabolism in rats and rabbits after subcutaneous administration. Oyo Yakuri (Pharmacometrics) 29:713-723, 1985.
8. Zelcer, N., Reid, G., Wielinga, P., Kuil, A., et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). J. Biochem. 371:361-367, 2003.
9. Karla, PK., Pal, D., Quinn, T., and Mitra, A.K. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int. J. Pharm. 336:12-21, 2007.
10. Karla, P.K., Pal, D., and Mitra, A.K. Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells. Exp. Eye Res. 84:53-60, 2007.
11. Dey, S., Patel, J., Anand, B.S., et al. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci. 44:2909-2918, 2003.
12. Yamaguchi, M., Yasueda, S., Isowaki, A., et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int. J. Pharma. 301:121-128, 2005.
13. Vandamme, T.F. Microemulsions as ocular drug delivery system: recent developments and future challenges. Prog. Retin. Eye Res. 21:15-34, 2002.
14. Tamilvanan, S., Gursoy, R.N., and Benita, S. Emulsion-based delivery systems for enhanced drug absorption. Business Briefing. Pharm. Tech. 131:156-162, 2002.
15. Marti-Mestres, G., and Nielloud, F. Emulsions in health care applications - an overview. J. Dispers. Sci. Technol. 23:419-439, 2002.
16. Inoue, J., et al. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 48:E-Abstract 2651, 2007.
17. Sakaki, H., et al. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 48:E-Abstract 2653, 2007.
18. Kida, T., et al. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 48:E-Abstract 2655, 2007.
19. Okumura, A., et al. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 48:E-Abstract 2652, 2007.
20. Ohji, M., et al. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 48:E-Abstract 3903, 2007.
21. Ohno, S., et al. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 48:E-Abstract 3904, 2007.
22. Mochizuki, M., et al. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 48:E-Abstract 3905, 2007.
23. Korenfeld, M., Silverstein, S., Cooke, D.L., Vogel, R., and Crockett, R.S. The Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J. Cataract Refract. Surg. 35:26-34, 2009.
24. DaVanzo, R. Association for Research in Vision and Ophthalmology. Invest. Ophthalmol. Vis. Sci. 50:E-Abstract 2697, 2009.
25. Nakano, S., Yamamoto, T., Kirii, E., Abe, S., and Yamashita, H. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch. Clin. Exp. Ophthalmol. 248:805-810, 2010.
26. Greenblatt, D. Elimination half-life of drugs: values and limitations. Annu. Rev. Med. 36:421-427, 1985.
27. Le Bourlais, C., Acar, L., Zia, H., et al. Ophthalmic drug delivery system - recent advances. Prog. Retin. Eye Res. 17:33-58, 1998.
28. Schoenwald, R.D., and Ward, R.L. Relationship between steroid permeability across excited rabbit cornea and octanol-water partition coefficients. J. Pharm. Sci. 67:786-788, 1978.
29. Yasueda, S., Kimura, M., Ohtori, A., et al. Analysis of an anti-inflammatory steroidal drug, difluprednate, in aqueous humor by combination of semi-micro HPLC and column switching method. J. Pharm. Biomed. Anal. 30:1735-1742, 2003.
30. Tajika, T., Takahashi, H., Sakai, Y., et al. Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion. Xenobiotica 40:569-577, 2010.
31. Ahmed, I., and Patton, T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26:584-587, 1985.
32. Kiffe, M., Schmid, D.G., and Bruin, G.J. Radioactivity detectors for high-performance liquid chromatography in drug metabolism studies. J. Liq. Chromatogr. 31:1593-1619, 2008.